AGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Agilon Health Inc. (AGL) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown a significant price increase in the regular market session, the overbought RSI, lack of strong proprietary trading signals, and mixed financial and analyst sentiment suggest caution. Holding the stock or waiting for a better entry point may be more prudent.
The stock's MACD is positive and expanding, indicating bullish momentum. However, the RSI of 93.384 suggests the stock is overbought, and the price is near a resistance level (R1: 28.405, R2: 33.547). Moving averages are converging, which could indicate potential price consolidation.
Hedge funds and insiders are significantly increasing their buying activity, which indicates confidence in the stock. The company has shown YoY improvements in revenue, net income, and EPS.
The stock is overbought according to RSI, and there is no recent AI Stock Picker or SwingMax signal. News of an investigation into potential fiduciary breaches by executives could weigh on sentiment. Analyst ratings and price targets reflect mixed opinions, with some maintaining Hold or Neutral ratings.
In Q4 2025, Agilon Health reported a 3.09% YoY increase in revenue to $1.57 billion. Net income improved by 78.54% YoY but remains negative at -$188.88 million. EPS also improved by 76.92% YoY to -0.46. Gross margin increased significantly but remains negative at -5.02%.
Analyst ratings are mixed, with price targets adjusted to reflect a 1-for-25 reverse stock split. TD Cowen and Deutsche Bank maintain Hold ratings, while Benchmark has a Buy rating. The adjusted price targets range from $13 to $33, reflecting uncertainty in the stock's valuation and future performance.
